Clinical Trial Update: Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of ziftomenib and mezigdomide in adolescents and adults with relapsed or refractory acute myeloid leukemia, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Kmt2a-rearranged Acute Myeloid Leukemia
• Npm1-mutant Acute Myeloid Leukemia

Drugs mentioned

• Mezigdomide (mezigdomide)
• Ziftomenib (ziftomenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML | Phase 1 | Status: NOT_YET_RECRUITING